AKRO - NASDAQ
Akero Therapeutics, Inc.
$54.65
+0.0000%Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotakro
Total Liabilities and Equity
Last Annual Value
825.89M
3-Year CAGR
62%
5-Year CAGR
43%
10-Year CAGR
104%
Akero Therapeutics, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Akero Therapeutics, Inc. NASDAQ:AKRO | 825.89M | 12.5% | 33.4% | N/A | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 1.14B | 21.4% | 26.5% | 56.9% | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 563.83M | 46.1% | 73.8% | 58.7% | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 1.56B | 27.8% | 17.4% | 10.8% | |
 Arcellx, Inc. NASDAQ:ACLX | 603.99M | -9.9% | 36.2% | N/A | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 769.28M | 30.4% | 62.5% | N/A | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 937.91M | 120.1% | 26.2% | N/A | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 715.73M | 24.8% | 27.7% | 47.6% | |
 Immunovant, Inc. NASDAQ:IMVT | 957.01M | 33.1% | 18.3% | N/A | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 1.74B | 44.7% | 23.5% | N/A |
Akero Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your AKRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.